Devicemakers slow to embrace green technology; Stryker says device tax will cost it $130M a year;

 @FierceMedDev: Budget battles could unravel the massive device/drug user fee renewal agreed to earlier this summer. More | Follow @FierceMedDev

 @MarkHFierce: Another day, another 510(k) for an Impella heart pump variation. The company is working hard to broaden its market. Release | Follow @MarkHFierce

 @DamianFierce: San Antonio's BiO2 Medical pulled in $12M to market its venous catheter. News | Follow @DamianFierce

> The medical device industry has been slow to embrace sustainability or pursue the recycling of used devices, Waste & Recycling News reports. Story

> Stryker's ($SYK) interim CEO Curt Hartman says that the medical device tax will cost his company about $130 million annually, according to MassDevice. Story

> Tissue Regeneration Systems, a developer of tissue-regeneration medical devices and related equipment, has secured $1 million in new financing. Item

> China has a robust demand for certain, hospital-focused medical devices made in the U.S., Buffalo Business First explains. Story

> Endologix ($ELGX) snagged a CE mark for Nellix, a device designed to seal abdominal aortic aneurysms. Article

> As medical device companies expand into emerging markets, more and more are using overseas CROs to conduct clinical trials, according to a new study. More

> Indian devicemaker Opto Circuits snagged regulatory approval in that country for its E-Magic Plus drug-eluting stent. News

Biotech News

 @FierceBiotech: What's killing biopharma's R&D success rate? Story | Follow @FierceBiotech

 @JohnCFierce: AZ does a China development deal on RA drug with WuXi AppTech. Kinda similar to SFJ pacts. Look for more of these. Report | Follow @JohnCFierce

> What's killing biopharma's R&D success rate? More

> Geron in meltdown as lead cancer drug crumbles in Phase II. Report

> Atlas R&D group banks $8M in virtual development deal. Story

> Peregrine soars on promising survival data for lung cancer drug. Article

Pharma News

 @FiercePharma: Truvada use expected to be limited in U.S. Story | Follow @FiercePharma

> FDA gives generic drugs 'super' status. Report

> Biogen Idec cashes out royalties on Benlysta. Article

> Budget impasse imperils FDA user fees programs. More

Biotech IT News

> Pharma flocks to social media analytics. Story

> Pinterest attracts more pharma outfits. Report

> ENCODE generates 15 trillion bytes of data for researchers. Article

> Informatics research may kill old-school databases. More

CRO News

> Top Emerging CRO Markets. Special Report

> Icon teams with Dublin university for drug development. Item

> FDA slaps DPT with warning letter over sterility concerns. Article

> CMO Patheon sells off clinical packaging biz. More

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.